Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. *Competing interests*: FGDR and GDP have been speakers or advisory board members for Pfizer; VMR has received funding from Pfizer. All other authors declare no competing interests.

Ethical approval: Ethical approval was given by the Ethical Committee of S. Giovanni Battista-Molinette Hospital.

References

- Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol 2012;12:29.
- [2] Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005;33:1529–33.
- [3] Dong H, Wang X, Dong Y, Lei J, Li H, You H, et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011;38:296–300.
- [4] Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010;54:4605–10.

Francesco G. De Rosa* Silvia Corcione Lorena Baietto Alessandra Ariaudo Giovanni Di Perri

Department of Medical Sciences, Infectious Diseases Clinic at Amedeo di Savoia Hospital, University of Turin, Corso Svizzera 164, 10149 Torino, Italy

V. Marco Ranieri

Department of Anesthesia and Critical Care Medicine, City of Health and Science, Ospedale S. Giovanni Battista-Molinette, University of Turin, Italy

Antonio D'Avolio

30 January 2013

CrossMark

Department of Medical Sciences, Infectious Diseases Clinic at Amedeo di Savoia Hospital, University of Turin, Corso Svizzera 164, 10149 Torino, Italy

* Corresponding author. Tel.: +39 011 439 3979; fax: +39 011 439 3882. *E-mail address:* francescogiuseppe.derosa@unito.it (F.G. De Rosa)

http://dx.doi.org/10.1016/j.ijantimicag.2013.01.016

Decrease in the incidence of meticillin-resistant *Staphylococcus aureus* nosocomial bloodstream infections in Taiwan

Sir,

In the recent review of the global epidemiology of meticillinresistant *Staphylococcus aureus* (MRSA) by Stefani et al. [1], they showed that MRSA remains highly prevalent in hospitals, especially in America, Asia and Malta. In contrast, the prevalence of hospital-acquired MRSA has declined in Austria, France, Ireland, the UK and Greece [1]. However, another recent study that enrolled 14 hospitals in Europe, North America and South America over a 10-year period (1998–2007) demonstrated that the incidence of nosocomial bloodstream infections (BSIs) was increasing and that the increased incidence was mainly due to antibiotic-resistant bacteria (ARB), including MRSA [2]. In that study, the MRSA incidence density (events per 100 000 patient-days) increased from 3.1 to 11.7 with an annual increase of 10% in seven ARBendemic hospitals [2]. In Taiwan, the annual report of the Taiwan Nosocomial Infections Surveillance system by the Department of Health of Taiwan showed that *S. aureus* was among the top three common pathogens causing BSIs in intensive care units, and more than 77% of *S. aureus* isolates were MRSA in 2011. These differences in MRSA incidence density may be due to geographical variation and their findings [1,2] might not be generalised to other places, such as Asia. We therefore retrospectively assessed the trend in incidence of nosocomial MRSA BSIs at an ARB-endemic medical centre in Taiwan.

This study was conducted at National Taiwan University Hospital (NTUH), a 2500-bed, academically affiliated medical centre providing both primary and tertiary care in northern Taiwan. The number of annual patient-days at the hospital increased from 624675 in 2000 to 763372 in 2010. To determine the temporal trend in nosocomial BSIs due to MRSA at NTUH, data on disk diffusion susceptibilities of S. aureus to oxacillin among isolates recovered from 2000 to 2010 were retrieved from annual summary documents. Definitions of nosocomial infections followed National Nosocomial Infections Surveillance guidelines [3]. Isolates of each species from each patient recovered within 7 days were considered as a single isolate. Susceptibility testing for S. aureus followed Clinical and Laboratory Standards Institute (CLSI) guidelines [4]. Staphylococcus aureus ATCC 25923 was used as a control strain for routine disk susceptibility testing [4]. Meticillin resistance among the S. aureus isolates was routinely screened for by measuring the growth of each isolate on a trypticase soy agar plate containing 6 mg/L oxacillin plus 2% NaCl at 35 °C in ambient air for 24 h [4]. The χ^2 test was used for dichotomous variables. The χ^2 test for trend was used to assess temporal trends in incidence densities, and Poisson regression was used to determine yearly change in incidence density as a percentage with 95% confidence intervals (CIs). Data were analysed using SPSS v.11.0 (SPSS Inc., Chicago, IL) and R v.2.15.2.

During the study period, a total of 21233 nosocomial BSIs were identified. Of these BSIs, 2240 infections were caused by *S. aureus*, 69.1% of which (n = 1547) were due to MRSA. During the period 2000–2010, the incidence density of all nosocomial BSIs increased from 254.7 to 308.3 per 100 000 patient-days (P<0.001), with an annual increase of 3.9% (95% CI 2.4–10.2%). The secular trends in incidence density of nosocomial MRSA and meticillinsusceptible *S. aureus* BSIs are shown in Fig. 1. For MRSA, the incidence density significantly decreased from 27.9 to 12.3 per 100 000 patient-days, with an annual decrease of 8.5% (95% CI 7.0–10.8%) over the 10-year study period (P<0.001). In addition,




Fig. 1. Secular trends in the incidence densities of nosocomial meticillin-resistant *Staphylococcus aureus* (MRSA) and meticillin-susceptible *S. aureus* (MSSA) blood-stream infections (P<0.001 for MRSA and P=0.91 for MSSA, χ^2 test for trend).

the ratio of MRSA isolates to all *S. aureus* isolates obtained from patients with nosocomial BSIs decreased from 68.8% in 2000 to 55.9% in 2010 (*P*=0.01).

In this study, we found that the incidence of nosocomial MRSA BSIs decreased even though there was an increase in the incidence of all nosocomial BSIs in Taiwan. Therefore, the total burden of nosocomial BSIs is most likely attributable to pathogens other than MRSA. This finding contrasts sharply with that reported by Ammerlann et al. [2] but is consistent with some European countries [1]. In response to the severe acute respiratory syndrome (SARS) epidemic in 2003, the infection prevention and control programme at NTUH was upgraded to include hand hygiene, antibiotic control policies, and an annual, intensive, project-based control programme. Implementation of these measures is one of the main reasons for the decrease in MRSA infections during the study period. In fact, the impact of these policies has been demonstrated to be directly associated with the decrease in rates of BSIs at NTUH [5].

In conclusion, these results show that the incidence of MRSA nosocomial BSIs decreased during the period 2000–2010 at NTUH and that the infection control measures at this hospital most likely played a major role in protecting against MRSA infections.

Funding: No funding sources.

Competing interests: None declared.

Ethical approval: Not required.

References

- Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh K, et al. Meticillin-resistant *Staphylococcus aureus* (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012;39: 273–82.
- [2] Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 2012;56:798–805.
- [3] Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32.
- [4] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
- [5] Chuang YC, Chen YC, Chang SC, Sun CC, Chen ML, Hsu LY, et al. Secular trends of healthcare-associated infections at a teaching hospital in Taiwan, 1981–2007. J Hosp Infect 2010;76:143–9.

Chih-Cheng Lai

Department of Intensive Care Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan

Sheng-Hsiang Lin^{a,b}

^a Department of Respiratory Therapy, Fu-Jen Catholic University, New Taipei, Taiwan

^b Department of Internal Medicine, New Taipei City Hospital, New Taipei, Taiwan

Wang-Huei Sheng

Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Po-Ren Hsueh^{a,b,*}

^a Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

^b Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

* Corresponding author. Present address: Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, Taiwan. Tel.: +886 2 2312 3456x65355; fax: +886 2 2322 4263. *E-mail address:* hsporen@ntu.edu.tw (P.-R. Hsueh)

4 February 2013

4 February 2013

CrossMark

http://dx.doi.org/10.1016/j.ijantimicag.2013.02.002

Tropheryma whipplei endocarditis relapses after treatment with trimethoprim/sulfamethoxazole

Sir,

Tropheryma whipplei is involved in classic Whipple's disease (WD), a chronic infection characterised by histological involvement of the small bowel [1]. The main manifestations are arthralgias and diarrhoea, but infective endocarditis is sometimes present [1]. One year or shorter treatment with oral trimethoprim/sulfamethoxazole preceded by 2 weeks of ceftriaxone is recommended by some authors [2]. However, *T. whipplei* is naturally resistant to trimethoprim, and acquired resistance to sulfonamides has been reported [3]. Here we report two more cases that relapsed following trimethoprim/sulfamethoxazole therapy.

In 2004, a 41-year-old man was hospitalised for weight loss, diarrhoea, abdominal pain and anaemia. He was diagnosed with WD based on positive periodic acid-Schiff (PAS) staining on a small bowel biopsy. The patient received oral trimethoprim/sulfamethoxazole (160/800 mg/day) for 18 months. Four years after the cessation of antibiotics, the patient was hospitalised because of progressive dyspnoea and weight loss. Transoesophageal echocardiography showed aortic valve vegetation and an altered mitral valve. Blood cultures were negative. Both removed valves were positive with PAS staining and specific PCR, allowing for the diagnosis of T. whipplei endocarditis. The entire folP sequence was obtained but did not show mutations previously reported to be associated with resistance [3]. A small bowel biopsy was positive for PAS staining and specific immunohistochemistry (Fig. 1A). Saliva and skin biopsy were both positive for T. whipplei with specific PCR. Treatment was initiated with oral doxycycline (200 mg/day), hydroxychloroquine (600 mg/day) and trimethoprim/sulfamethoxazole (320/1600 mg/day). The patient was unfortunately lost to follow-up.

In 2008, a 61-year-old man was hospitalised for arthralgias, weight loss and lymphadenopathy. He was diagnosed with WD based on positive PAS staining and specific immunohistochemistry on a small bowel biopsy. He had aortic and mitral insufficiencies, which were thought to be degenerative. Treatment with intravenous ceftriaxone (2g/day for 2 weeks) followed by trimethoprim/sulfamethoxazole (320/1600 mg/day) was initiated, with rapid clinical improvement. Six months after the initiation of this regimen the patient developed dyspnoea and underwent replacement of his aortic and mitral valves. Both valves were positive with PAS staining and specific immunohistochemistry (Fig. 1B). Specific PCR was positive for the mitral valve. Only a partial sequence of *folP* was obtained. None of the mutations that were previously reported in the T. whipplei folP sequence were detected [3]. The antibiotic regimen was switched to doxycycline (200 mg/day) and hydroxychloroquine (600 mg/day) for 2 years, with clinical improvement, followed by lifelong doxycycline (200 mg/day), and the patient is currently apparently cured.

Management of patients with classic WD is still difficult and patients may relapse as endocarditis. There is an ongoing controversy on the use of trimethoprim/sulfamethoxazole for WD [2]. In fact, it was used empirically in sporadic cases until genomic analysis and biological assays found that trimethoprim is not